-
Giving research participants their voice: assessing comprehension in the informed consent process
Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorial: Clinical Investigation
-
Giving research participants their voice: assessing comprehension in the informed consent process
Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorial: Clinical Investigation
-
Giving research participants their voice: assessing comprehension in the informed consent process
Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorial: Clinical Investigation
-
Giving research participants their voice: assessing comprehension in the informed consent process
Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorial: Clinical Investigation
-
Giving research participants their voice: assessing comprehension in the informed consent process
Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorial: Clinical Investigation
-
Giving research participants their voice: assessing comprehension in the informed consent process
Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorial: Clinical Investigation
-
Giving research participants their voice: assessing comprehension in the informed consent process
Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorial: Clinical Investigation
-
Giving research participants their voice: assessing comprehension in the informed consent process
Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorial: Clinical Investigation
-
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Grazia D Femminella & Paul Edison
Editorial: Clinical Investigation
-
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Grazia D Femminella & Paul Edison
Editorial: Clinical Investigation
-
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Grazia D Femminella & Paul Edison
Editorial: Clinical Investigation
-
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Grazia D Femminella & Paul Edison
Editorial: Clinical Investigation
-
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Grazia D Femminella & Paul Edison
Editorial: Clinical Investigation
-
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Grazia D Femminella & Paul Edison
Editorial: Clinical Investigation
-
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Grazia D Femminella & Paul Edison
Editorial: Clinical Investigation
-
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Grazia D Femminella & Paul Edison
Editorial: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation